RNAi-mediated β-catenin inhibition impairs tumor growth in multiple immunocompetent CTNNB1-mutated and non-CTNNB1-mutated HCC mouse models with durable response in early-stage disease setting. This evidence concerns the gene CTNNB1 and neoplasm.